Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TY-9591 + Chemotherapy in EGFR-Mutated NSCLC
NCT06672068Phase 2Not yet recruiting
- Sponsor
- TYK Medicines
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of asandeutertinib in non-small cell lung cancer (NSCLC), sponsored by TYK Medicines. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
asandeutertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06672068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672068.